Bristol-Myers Squibb Company
I · Analiza AI
Pe scurt
Bristol-Myers Squibb discovers, develops, manufactures, and sells prescription medicines worldwide, focusing on cancer treatments (Opdivo, Yervoy, Breyanzi), immune system drugs (Orencia, Zeposia), blood disorder treatments (Reblozyl, Revlimid), and cardiovascular medicines (Eliquis) [Yahoo Finance]. The company sells through wholesalers, specialty pharmacies, hospitals, and government agencies across global markets [Yahoo Finance].
Bristol-Myers Squibb is a large pharmaceutical company that develops and sells drugs for cancer, immune diseases, heart conditions, and neurological disorders [Yahoo Finance]. The company generates $48.2B in annual revenue, maintains a $119B market cap, and is financially healthy with strong cash flow [Yahoo Finance]. Recent news highlights aggressive AI partnerships with Anthropic and Tempus AI to accelerate drug discovery, plus a major $1B manufacturing expansion in Houston [Yahoo Finance].
Bristol-Myers Squibb is financially healthy with strong profitability and solid cash generation, though revenue is flat year-over-year [Yahoo Finance].
Scor Sentinellis
7.4/10
Financially healthy
Capitalizare bursieră
$119.1B
Venituri (12 luni)
$48.2B
II · Știri recente
Ce a mișcat prețul
6 stories · ranked by relevance
- macro2026-05-20
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
Yahoo Finance
- macro2026-05-19
How The Bristol Myers Squibb (BMY) Story Is Shifting Around Pipeline Hopes And Patent Risks
Simply Wall St
- macro2026-05-20
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Yahoo Finance
- macro2026-05-18
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts
Benzinga
- macro2026-05-19
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks
- macro2026-05-18
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist
Simply Wall St
Premium · gratuit cu orice cont
Revenue is flat year-over-year at -0.2%, signaling potential challenges in maintaining growth momentum as key drug patents approach expiration [Yahoo Finance].
Riscuri
4
Oportunități
6
Semnale de alarmă
1
Conducere
10
Încă 20 de constatări în raportul complet — gratuit cu orice cont.
Deblochează analiza completă Bristol-Myers Squibb Company
Fă-ți un cont gratuit ca să vezi raportul complet generat de AI, cu surse citate în text.
- 4 riscuri, 6 oportunități și 1 semnal de alarmă — fiecare cu sursa lui
- Peste 100 de indicatori financiari, cu grafice și comparații
- Rezumate complete ale știrilor, cu linkuri către surse
- Echipa de conducere și remunerația
- Export PDF pentru citit offline
III · Companii similare
Ai putea citi și
Same sector · Healthcare or comparable health
Vrei compania asta pe lista ta?